DexCom entered into a warrant termination agreement with Bank of America, N.A. (BofA) on February 13, 2024 to terminate common stock warrants it had issued to BofA.

1. 01

   DexCom entered into a warrant termination agreement with Bank of America, N.A. (BofA) on February 13, 2024 to terminate common stock warrants it had issued to BofA.

2. 02

   Under the agreement, the company will terminate the portion of the BofA Warrant Transactions covering an aggregate of 10.3 million shares of common stock.

3. 03

   DexCom said it will deliver shares of common stock to BofA as consideration for the warrant termination, with the number determined by the daily volume-weighted average price over the averaging period set in the agreement. It said the averaging period is expected to be completed in Q1 2024.

4. 04

   DexCom said the Warrant Transactions with BofA and JPM were entered into in connection with the issuance of 0.75% Convertible Senior Notes due 2023, and that the warrants it agreed to sell to the two banks cover up to approximately 20.7 million shares of common stock.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.